Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Cash Flow (2016 - 2025)

Vanda Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $14.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 632.76% year-over-year to $14.8 million; the TTM value through Dec 2025 reached -$17.5 million, up 47.55%, while the annual FY2025 figure was -$17.5 million, 47.55% up from the prior year.
  • Net Cash Flow for Q4 2025 was $14.8 million at Vanda Pharmaceuticals, up from -$10.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $219.1 million in Q1 2023 and bottomed at -$204.1 million in Q2 2023.
  • The 5-year median for Net Cash Flow is -$4.7 million (2021), against an average of $1.2 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 5078.73% in 2022 before it tumbled 2224.23% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $1.6 million in 2021, then surged by 5078.73% to $85.4 million in 2022, then crashed by 155.61% to -$47.5 million in 2023, then skyrocketed by 104.25% to $2.0 million in 2024, then soared by 632.76% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Net Cash Flow are $14.8 million (Q4 2025), -$10.8 million (Q3 2025), and -$30.9 million (Q2 2025).